A recent phase II trial has shown that bevacizumab is tolerated by patients with nasopharyngeal carcinoma. The trial assessed patients with grade IIB–IVB disease and combined treatment with bevacizumab and cisplatin with intensity-modulated radiation therapy. There were no grade 5 adverse events, which was one of the end points, and no grade 3 or 4 hemorrhages occurred. Although this was a single-arm trial, the investigators reported that the treatment “might delay the progression of subclinical distant disease.”